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Background: Overlapping first generation drug eluting stents (DES) have been demon-
strated in preclinical models to show evidence of a persistent inflammatory response,
fibrin deposition and delayed endothelialisation. The SIRTAX (Sirolimus-Eluting Versus
Paclitaxel-Eluting Stents for Coronary Revascularization) Trial (n1012) associated the
implantation of overlapping first generation DES with impaired angiographic and adverse
3-year clinical outcomes, including death or myocardial infarction (MI).
Methods: Patient level data from 5 controlled studies of the RESOLUTE Global Clinical
Program evaluating the RESOLUTE zotarolimus-eluting stent (R-ZES) were pooled
(n5130). Enrolment criteria encompassed more complex patients, including acute MI,
long lesions, unprotected left main, bifurcations, total occlusions, bypass grafts & visible
thrombus. The position of the R-ZES in relation to the previous implanted stents during
the index or staged procedures were reported by the study site as either ‘separate,’
‘abutting’ or ‘overlapping.’ Comparisons of clinical outcomes – using propensity score
adjustment of baseline anatomical and clinical characteristics – were undertaken between
patients implanted with at least one overlapping DES against patients with no overlapping
DES (Kaplan Meier analyses).
Results: 644 of 5130 study patients (12.6%) underwent overlapping DES implantation.
Baseline characteristics indicated that the implantation of overlapping DES compared to
non-overlapping DES (n4486) were performed more frequently in the RCA and in more
complex coronary lesions. Thirty day, 1 & 2 year clinical outcomes indicated comparable
all-cause death (2 year overlap vs. non overlap: 5.1% vs. 3.5%, p0.13), cardiac death
(3.0% vs. 2.1%, p0.36), MACE (13.3% vs. 10.7%, p0.19), target lesion (10.9% vs.
9.0%, p0.41) & target vessel (12.8% vs. 10.6%, p0.25) failure, and stent thrombosis
(ARC definite/probable 1.4% vs. 0.9%, p0.16).
Conclusions: The adverse clinical outcomes associated with 1st generation DES were
not apparent with 2nd generation DES. Overlapping second generation DES (compared
to the non overlap) is safe & effective with comparable 2 year clinical outcomes, including
repeat revascularisation.
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Background: The new drug-eluting stent BioMime™ (Meril Life Sciences Pvt. Ltd.,
Gujarat, India) is composed of an ultra-thin platform (strut thickness 0.0026’’), a
biodegradable polymer and sirolimus. Its clinical efficacy and safety had already been
demonstrated. However, the impact of the BioMime™ SES on populations from daily
practice with complex lesions is not fully determined.
Methods: The meriT-2 was a prospective, non-randomized, multicenter study, with
minimally selected patients and evaluated clinical and safety performance of the
BioMime™ SES in the treatment of complex patients from daily practice. Native
coronary lesions ranging from 2.5-3.5 mm in diameter and with 37 mm in length, and
chronic total occlusions were included. Lesions located at the left main coronary or in
saphenous vein grafts, or patients with acute myocardial infarction (MI) or left ventricular
ejection fraction30% were excluded. Clinical follow-up (FU) was performed in 1, 8 and
12 months; angiographic FU at 8 months. The primary outcomes were major adverse
cardiac events (MACE: death, MI and target-lesion revascularization –TLR) in 1 month,
and late lumen loss (LLL) in 8 months.
Results: A total of 242 patients were included. Mean age was 56.7 years, 37% diabetics,
32% had previous MI, most with type B2/C lesions, 40% with multiarterial disease and
52% presenting in acute coronary syndrome. Medians of lesion length, reference diameter
and % stentosis were: 15.8mm [13.47-21.42], 2.79mm [2.42-2.99], and 89.8 [83.2-93.2],
respectively. A total of 363 stents were implanted. There were no MACE afer 30 days and
the LLL in 8 months (n132) was 0.15 mm [0.09-0.33]. Cumulative rates of MACE in
12 months were 5.7% (0.5% cardiac death; 4.7% TLR). There were 3 cases of stent
thrombosis (ST) - 1 acute, 1 sub-acute and 1 late.
Conclusions: In this multicenter evaluation of complex “real-world” patients, the new
BioMime™ SES has shown excellent efficacy and safety, with low rates of MACE and
ST in 1 year, as well as low values of LLL.
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Background: Diffuse long lesions are commonly encountered in routine clinical practice
and often lead to use long or overlapping stents. Limited data are available on the
long-term efficacy and safety of long drug-eluting stents (DES) in this complex lesion
subset. We investigated the long-term efficacy and safety of38mm-long DES in patients
undergoing stent implantation for de novo diffuse long lesions.
Methods: 129 consecutive patients who underwent coronary artery stenting with
38mm-long DES in real world practice were included. Study endpoints were major
adverse cardiac events including cardiac death, myocardial infarction, repeat revascular-
ization and stent thrombosis.
Results: 129 pts with 153 lesions were enrolled, 85.2% were male, mean age 58.210
yrs. Lesions were treated with at least one 38mm second generation DES, all post-dilated
at high atmosphere (20 atm) with NC balloons. Mean stent size was 3.00.2 mm, mean
stent length was 54.5 mm. Two-year clinical outcomes were compared between diabetic
(DM) (n40) and non-DM patients (n89). Baseline characteristics were similar in the
two groups as were mean stent length (50.2  13.1 mm in DM and 54.5  15.7 in
non-DM, p  0.12). Mean follow-up duration was 433275 days, and 2-yr cumulative
major adverse cardiac events were significantly lower in the non-DM than in DM group
(5.6% in non-DM vs 10% in DM, p  0.03). Clinically driven TLR was 5.4% and no
cardiac death was reported. There was 1 case defined as late stent thrombosis. The
independent predictors of repeat revascularization were insulin treated type 2 diabetes
mellitus, reference vessel diameter (RVD) 2.75 mm and the use of overlapping DES
longer than 60 mm.
Conclusions: The use of 38mm DES for treatment of complex diffuse disease is safe
and effective with an acceptably low 2-year MACE rate. The need for repeat revascular-
ization was increased with overlapping long DES, small RVD, and insulin treated DM
patients.
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Background: Dissections during stenting are rare but can lead to clinical complications
and necessitate use of a secondary stent thus increasing direct cost of the procedure. This
study examined four popular DES products (Resolute Integrity-Medtronic; Xience Prime
and Xience V-Abbott; and Promus Element-Boston Scientific) using a bench model
developed to explore factors that contribute to dissections.
Methods: Devices (n5) were inserted into mock vessels designed to match the
compliance of a native artery and inflated from nominal to 20-atm pressure. Inner
diameters and outward pressures against the vessel wall were ascertained at 500-m
increments at each inflation pressure. Desired forces within stent body were compared to
undesired forces associated with balloon transition and overhang.
Results: Resolute Integrity and Promus Element exerted consistent pressures within the
device body and decreasing forces in the distal balloon overhang regions. Xience devices
flared as they approached the distal transition, and highest vessel stretch was observed in
the balloon overhang. This flaring or “trumpeting” phenomenon was not observed in other
DES.
TUESDAY, OCTOBER, 23, 8:00 AM–10:00 PMwww.jacc.tctabstracts2012.com







Conclusions: This “trumpeting” may also partially explain the observed use of more
Xience stents per lesion compared to Resolute (1.180.45 vs. 1.150.42, p0.02) in the
Resolute All Comers (RAC) trial. The primary cause for secondary stenting in RAC was
“to stabilize target lesion” which includes procedural complications including dissection
or perforations.
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Background: Endothelium dysfunction is among the possible causes related to higher
thrombosis rates after 1st generation DES. Whether the presence of durable polymer or
high anti-proliferative drug dose, or both, can be responsible for this phenomenon is not
clear. In the present study we compared the endothelial function following the implant of
a polymer-free DES with a nanothin-microporous hydroxyapatite surface coating impreg-
nated with a low-dose of Sirolimus (55g) to a BMS equivalent coated with a
hydroxyapatite surface (Vestacor stent).
Methods: The Vestasync II is a randomized, double-blinded trial with 20 pts (10 in each
group) with de novo lesions in native coronary arteries of 3.0-3.5mm diameter and 
14mm in length. The primary goal was to compare the vasomotricity after implantation
of stents with the same platform, with and without drug elution. Endothelial function was
assessed with atrial pacemaker stimulation (20 ppm over basal cardiac frequency until
reach 150 ppm) and the lumen diameter was measured at 5 mm of proximal and distal
stent edges and in a control segment, in different stages (at rest, at successive phases of
stimulli and after nitroglycerin I.C infusion).
Results: As shown in the figure, there was a negative variation in luminal diameter
between basal and maximum stimulli at proximal (10%) and distal (8%) edges of both
groups. Among control segments this variation was less than 3%, an acceptable variation
of QCA method.
Conclusions: The elution of sirolimus does not seem to interfere in endotelial function
8 months after polymer-free hydroxiapatite coating stent implantation.
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Background: Percutaneous intervention (PCI) for degenerated saphenous vein graft
(SVG) lesions are well known for high rates of no-reflow, restenosis (ISR) and stent
thrombosis. Covered stents have been tried in an aim to trap the debris to minimize
no-reflow and ISR. Two types of covered stents have been used for SVG lesions:
pericardium covered stent (PCS) & polytetrafluroethylene (PTFE) covered stent. We
present our long-term follow-up data following the use of both types of covered stents in
our practice.
Methods: Between 1997 and 2004, 52 patients (mean age: 67.14 years) with 65 lesions
in SVG were treated with PTFE covered stents as a part of multicenter trial (RECOV-
ERS). Between 2003 and 2007, 33 patients (mean age: 67.78 years) with 48 SVG lesions
were treated with pericardium-covered stents covered stents as a part of multicenter trial
(SLEEVE II).
Results: All case had TIMI3 flow post PCI and there were no immediate post-procedural
complications. There were no significant differences in the baseline characteristics except
that mean length of PCS were significantly longer than PTFE covered stents (32.3 mm vs
25.1 mm, p0.001). At 5-year follow-up, the rates of TLR was [PTFE: 12 (18.5%), PCS:
13 (27%) p0.17], TVR was [PTFE: 14 (21.5%), PCS: 16 (33%) p0.07]. During the
5-year follow-up period, 8 patients (15%) in the PTFE group and 2 patients (6%) in the
PCS group had died; p0.33. The MACE defined as death, MI, clinically driven TVR
occurred in 34 of 52 PTFE patients (63%) vs. 18 of 33 PCS patients (54.5%); p0.2.
There were two reported cases of definite very late stent thrombosis in the PCS group, but
none in the PTFE group.
Conclusions: The 5 year follow-up data shows no significant differences in the clinical
endpoints between the two covered stents, although numerically it was slightly worse in
the PCS group. The rates of TLR and TVR are not discouraging in either stents given the
complexity of SVG lesions. Considering the complexity of the lesions treated and the
absence of no-reflow, covered stents may provide additional protection. Since there are no
very long-term follow-up with other stents in SVG, we cannot compare these results with
the traditional stents.
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Background: In this study, we investigated the safety of ambulatory percutaneous
coronary intervention (PCI) in high-risk patients according to age, creatinine, ejection
fraction (ACEF) scores.
Methods: The ambulatory PCI group consisted of all consecutive PCI with same-day
discharges at Mount Sinai Hospital from January 1, 2003 to March 31, 2011 who had
follow-up data. The overnight group consisted of all PCI outpatients in 2004 who were
then hospitalized for at least one night. Patients were stratified into two groups based on
ACEF score: low (1.100) and high (1.100). The primary endpoint was a 30-day major
adverse cardiac events (MACE: readmission, all-cause death, and myocardial infarction
(MI).
Results: Out of 4932 patients, 3216 or 65.2% were in the ambulatory group and the rest
(1716) were in the control group. The average age was 61.5 years and were no significant
differences in baseline characteristics. Overall 30-day MACE occurred in similar
frequency in both groups (Table), in high and low ACEF scores.
TUESDAY, OCTOBER, 23, 8:00 AM–10:00 PM www.jacc.tctabstracts2012.com
B190 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stents
P
O
ST
E
R
S
